Study Using PET/CT to Characterize the Effect of Reslizumab on Airway Inflammation
- Study Title
- An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
- Teva Identifier
- C38072-AS-40105
- ClinicalTrials.gov Identifier
- NCT02937168
- Study Status
- Terminated
- Trial Condition(s)
- Asthma
- Interventions
- Drug: Reslizumab | Drug: Fludeoxyglucose F 18 (FDG) | Drug: Placebo
Study Description
Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult
- Age Range
- 18 Years to 50 Years
- Trial Duration
- May 8, 2017 - May 24, 2017
- Phase
- Phase 4
